-
Je něco špatně v tomto záznamu ?
Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol
J. Stutterheim, P. de Lorenzo, IM. van der Sluis, J. Alten, P. Ancliffe, A. Attarbaschi, L. Aversa, JM. Boer, A. Biondi, B. Brethon, P. Diaz, G. Cazzaniga, G. Escherich, A. Ferster, RS. Kotecha, B. Lausen, AW. Leung, F. Locatelli, L. Silverman,...
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- akutní lymfatická leukemie komplikace mortalita patologie MeSH
- analýza přežití MeSH
- kojenec MeSH
- lidé MeSH
- prognóza MeSH
- reziduální nádor etiologie patologie MeSH
- výsledek terapie MeSH
- zárodečné buňky MeSH
- Check Tag
- kojenec MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
BACKGROUND: The outcome of infants with KMT2A-germline acute lymphoblastic leukaemia (ALL) is superior to that of infants with KMT2A-rearranged ALL but has been inferior to non-infant ALL patients. Here, we describe the outcome and prognostic factors for 167 infants with KMT2A-germline ALL enrolled in the Interfant-06 study. METHODS: Univariate analysis on prognostic factors (age, white blood cell count at diagnosis, prednisolone response and CD10 expression) was performed on KMT2A-germline infants in complete remission at the end of induction (EOI; n = 163). Bone marrow minimal residual disease (MRD) was measured in 73 patients by real-time quantitative polymerase chain reaction at various time points (EOI, n = 68; end of consolidation, n = 56; and before OCTADAD, n = 57). MRD results were classified as negative, intermediate (<5∗10-4), and high (≥5∗10-4). RESULTS: The 6-year event-free and overall survival was 73.9% (standard error [SE] = 3.6) and 87.2% (SE = 2.7). Relapses occurred early, within 36 months from diagnosis in 28 of 31 (90%) infants. Treatment-related mortality was 3.6%. Age <6 months was a favourable prognostic factor with a 6-year disease-free survival (DFS) of 91% (SE = 9.0) compared with 71.7% (SE = 4.2) in infants >6 months of age (P = 0.04). Patients with high EOI MRD ≥5 × 10-4 had a worse outcome (6-year DFS 61.4% [SE = 12.4], n = 16), compared with patients with undetectable EOI MRD (6-year DFS 87.9% [SE = 6.6], n = 28) or intermediate EOI MRD <5 × 10-4 (6-year DFS 76.4% [SE = 11.3], n = 24; P = 0.02). CONCLUSION: We conclude that young age at diagnosis and low EOI MRD seem favourable prognostic factors in infants with KMT2A-germline ALL and should be considered for risk stratification in future clinical trials.
Berlin Frankfurt Miu nster Group Germany Kiel Germany
Center of Bioinformatics Biostatistics and Bioimaging University of Milano Bicocca Monza Italy
Chilean National Pediatric Oncology Group Santiago Chile
Czech Working Group for Pediatric Hematology Prague Czech Republic
Dana Farber Cancer Institute Pediatric Oncology Boston MA USA
Department of Immunology Erasmus University Medical Center the Netherlands
Department of Pediatric Hematology University Robert Debre Hospital APHP Paris France
Dutch Childhood Oncology Group Utrecht the Netherlands
European Organisation for Research and Treatment of Cancer Children Leukemia Group Brussels Belgium
German Cooperative Study Group for Childhood Acute Lymphoblastic Leukemia Hamburg Germany
Oncode Institute Utrecht the Netherlands
Pediatric Oncology Princess Máxima Center for Pediatric Oncology Utrecht the Netherlands
Rigshospitalet University Hospital Department of Pediatrics Copenhagen Denmark
St Anna Children's Hospital Pediatric Hematology and Oncology Austria
Telethon Kids Cancer Centre Telethon Kids Institute University of Western Australia Perth Australia
United Kingdom Children Cancer Study Group London United Kingdom
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22011461
- 003
- CZ-PrNML
- 005
- 20220506130514.0
- 007
- ta
- 008
- 220425s2022 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejca.2021.10.004 $2 doi
- 035 __
- $a (PubMed)34785111
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Stutterheim, J $u Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. Electronic address: j.stutterheim@prinsesmaximacentrum.nl
- 245 10
- $a Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol / $c J. Stutterheim, P. de Lorenzo, IM. van der Sluis, J. Alten, P. Ancliffe, A. Attarbaschi, L. Aversa, JM. Boer, A. Biondi, B. Brethon, P. Diaz, G. Cazzaniga, G. Escherich, A. Ferster, RS. Kotecha, B. Lausen, AW. Leung, F. Locatelli, L. Silverman, J. Stary, T. Szczepanski, VHJ. van der Velden, A. Vora, J. Zuna, M. Schrappe, MG. Valsecchi, R. Pieters
- 520 9_
- $a BACKGROUND: The outcome of infants with KMT2A-germline acute lymphoblastic leukaemia (ALL) is superior to that of infants with KMT2A-rearranged ALL but has been inferior to non-infant ALL patients. Here, we describe the outcome and prognostic factors for 167 infants with KMT2A-germline ALL enrolled in the Interfant-06 study. METHODS: Univariate analysis on prognostic factors (age, white blood cell count at diagnosis, prednisolone response and CD10 expression) was performed on KMT2A-germline infants in complete remission at the end of induction (EOI; n = 163). Bone marrow minimal residual disease (MRD) was measured in 73 patients by real-time quantitative polymerase chain reaction at various time points (EOI, n = 68; end of consolidation, n = 56; and before OCTADAD, n = 57). MRD results were classified as negative, intermediate (<5∗10-4), and high (≥5∗10-4). RESULTS: The 6-year event-free and overall survival was 73.9% (standard error [SE] = 3.6) and 87.2% (SE = 2.7). Relapses occurred early, within 36 months from diagnosis in 28 of 31 (90%) infants. Treatment-related mortality was 3.6%. Age <6 months was a favourable prognostic factor with a 6-year disease-free survival (DFS) of 91% (SE = 9.0) compared with 71.7% (SE = 4.2) in infants >6 months of age (P = 0.04). Patients with high EOI MRD ≥5 × 10-4 had a worse outcome (6-year DFS 61.4% [SE = 12.4], n = 16), compared with patients with undetectable EOI MRD (6-year DFS 87.9% [SE = 6.6], n = 28) or intermediate EOI MRD <5 × 10-4 (6-year DFS 76.4% [SE = 11.3], n = 24; P = 0.02). CONCLUSION: We conclude that young age at diagnosis and low EOI MRD seem favourable prognostic factors in infants with KMT2A-germline ALL and should be considered for risk stratification in future clinical trials.
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a zárodečné buňky $7 D005854
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kojenec $7 D007223
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a reziduální nádor $x etiologie $x patologie $7 D018365
- 650 _2
- $a akutní lymfatická leukemie $x komplikace $x mortalita $x patologie $7 D054198
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a analýza přežití $7 D016019
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a de Lorenzo, P $u Center of Bioinformatics, Biostatistics and Bioimaging, University of Milano-Bicocca, Monza, Italy; Pediatrics, School of Medicine and Surgery, University of Milano- Bicocca, Fondazione MBBM/San Gerardo Hospital, Monza, Italy
- 700 1_
- $a van der Sluis, I M $u Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands
- 700 1_
- $a Alten, J $u Pediatrics, University Medical Center Schleswig-Holstein, Christian-Albrechts-University of Kiel, Germany
- 700 1_
- $a Ancliffe, P $u United Kingdom Children Cancer Study Group, London, United Kingdom
- 700 1_
- $a Attarbaschi, A $u St Anna Children's Hospital, Pediatric Hematology and Oncology, Austria
- 700 1_
- $a Aversa, L $u GATLA, Buenos Aires, Argentina
- 700 1_
- $a Boer, J M $u Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Oncode Institute, Utrecht, the Netherlands
- 700 1_
- $a Biondi, A $u Pediatrics, School of Medicine and Surgery, University of Milano- Bicocca, Fondazione MBBM/San Gerardo Hospital, Monza, Italy
- 700 1_
- $a Brethon, B $u Department of Pediatric Hematology, University Robert Debre Hospital, APHP, Paris, France
- 700 1_
- $a Diaz, P $u Chilean National Pediatric Oncology Group, Santiago, Chile
- 700 1_
- $a Cazzaniga, G $u Tettamanti Research Center, Pediatrics, School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy
- 700 1_
- $a Escherich, G $u German Cooperative Study Group for Childhood Acute Lymphoblastic Leukemia, Hamburg, Germany
- 700 1_
- $a Ferster, A $u European Organisation for Research and Treatment of Cancer Children Leukemia Group, Brussels, Belgium
- 700 1_
- $a Kotecha, R S $u Australian and New Zealand Children's Haematology/Oncology Group, Perth Children's Hospital, Perth, Australia; Telethon Kids Cancer Centre, Telethon Kids Institute, University of Western Australia, Perth, Australia
- 700 1_
- $a Lausen, B $u Rigshospitalet, University Hospital, Department of Pediatrics, Copenhagen, Denmark
- 700 1_
- $a Leung, Alex Wk $u The Chinese University of Hong Kong, Shatin, Hong Kong, Special Administrative Region, People's Republic of China
- 700 1_
- $a Locatelli, F $u Department of Pediatric Haematology and Oncology, IRCCS Ospedale Pediatrico Bambino Gesù, Sapienza University of Rome, Rome, Italy
- 700 1_
- $a Silverman, L $u Dana-Farber Cancer Institute, Pediatric Oncology, Boston, MA, USA
- 700 1_
- $a Stary, J $u Czech Working Group for Pediatric Hematology, Prague, Czech Republic
- 700 1_
- $a Szczepanski, T $u Polish Pediatric Leukemia/Lymphoma Study Group, Department of Pediatric Hematology and Oncology, Medical University of Silesia, Zabrze, Katowice, Poland
- 700 1_
- $a van der Velden, V H J $u Department of Immunology, Erasmus University Medical Center, the Netherlands
- 700 1_
- $a Vora, A $u United Kingdom Children Cancer Study Group, London, United Kingdom
- 700 1_
- $a Zuna, J $u CLIP, Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
- 700 1_
- $a Schrappe, M $u Berlin-Frankfurt-Miu ( ̈)nster Group Germany, Kiel, Germany
- 700 1_
- $a Valsecchi, M G $u Center of Bioinformatics, Biostatistics and Bioimaging, University of Milano-Bicocca, Monza, Italy
- 700 1_
- $a Pieters, R $u Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Dutch Childhood Oncology Group, Utrecht, the Netherlands
- 773 0_
- $w MED00009626 $t European journal of cancer (Oxford, England : 1990) $x 1879-0852 $g Roč. 160, č. - (2022), s. 72-79
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34785111 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506130506 $b ABA008
- 999 __
- $a ok $b bmc $g 1789185 $s 1162659
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 160 $c - $d 72-79 $e 20211113 $i 1879-0852 $m European journal of cancer $n Eur J Cancer $x MED00009626
- LZP __
- $a Pubmed-20220425
